Premium
Clinicopathological and prognostic characteristics of CD56‐negative multiple myeloma
Author(s) -
Sahara Naohi,
Takeshita Akihiro,
Shigeno Kazuyuki,
Fujisawa Shinya,
Takeshita Kaori,
Naito Kensuke,
Ihara Michio,
Ono Takaaki,
Tamashima Sadahiro,
Nara Kenji,
Ohnishi Kazunori,
Ohno Ryuzo
Publication year - 2002
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2002.03513.x
Subject(s) - multiple myeloma , incidence (geometry) , medicine , bence jones protein , beta 2 microglobulin , gastroenterology , plasma cell , plasma cell myeloma , disease , overall survival , pathology , immunology , antibody , immunoglobulin light chain , physics , optics
Summary. We analysed CD56 expression in 70 patients with multiple myeloma (MM) to determine its clinicopathological and prognostic significance. Fifty‐five (79%) patients were CD56 + . CD56 – patients ( n = 15) had higher β 2 microglobulin levels and a higher incidence of extramedullary disease, Bence Jones protein, renal insufficiency and thrombocytopenia than CD56 + patients. Their myelomas more frequently had a plasmablastic morphology. Overall survival was significantly lower in CD56 – than CD56 + patients (22 vs 63 months, P = 0·0002). We conclude that CD56 – MM is a discrete entity associated with more aggressive disease. The higher incidence of plasmablastic cases suggested that CD56 – MM may develop from a less mature plasma cell than CD56 + MM.